Research progress in vaccines of SARS-CoV-2.
- Author:
Xinbin GE
1
;
Qigan QU
1
;
Zeguang WANG
1
;
Shungeng ZHANG
1
;
Yan CHI
1
;
Chunhui SHAN
1
;
Ruihan LIU
2
,
3
;
Qing ZHAO
2
,
4
Author Information
1. School of Clinical Medicine, Jining Medical University, Jining 272007, China.
2. School of Clinical Medicine, Jining Medical University, Jining 272007
3. Department of Paediatrics, Affiliated Hospital of Jining Medical University, Jining 272029, China. *Corresponding authors, E-mail: ruihanliu1987@163.com.
4. Department of Paediatrics, Affiliated Hospital of Jining Medical University, Jining 272029, China. *Corresponding authors, E-mail: 15254768178@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
SARS-CoV-2/genetics*;
COVID-19/prevention & control*;
Protein Subunits;
Vaccines, DNA;
Nucleocapsid Proteins
- From:
Chinese Journal of Cellular and Molecular Immunology
2023;39(10):946-951
- CountryChina
- Language:Chinese
-
Abstract:
Since the outbreak of corona virus disease 2019 (COVID-19), viral strains have mutated and evolved. Vaccine research is the most direct and effective way to control COVID-19. According to different production mechanisms, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines included inactivated virus vaccine, live attenuated vaccine, mRNA vaccine, DNA vaccine, viral vector vaccine, virus-like particle vaccine and protein subunit vaccine. Among them, viral protein subunit vaccine has a wide application prospect due to its high safety and effectiveness. Viral nucleocapsid protein has high immunogenicity and low variability which could be a new direction for vaccine production. We summarized the current development of vaccine research by reviewing the current progress, vaccine safety and vaccine immune efficiency. It is hoped that the proposed possible development strategies could provide a reference for epidemic prevention work in future.
